Taiwan Biosim Company, Limited primarily represents biosimilars from multinational pharmaceutical (MNC pharma) companies. Biosimilars are the mainstream trend in the future development of new drugs, and the market is growing rapidly. Currently, the European Union is the fastest-growing and most mature market, followed by the United States, other advanced countries, and Taiwan. The purpose of developing biosimilars is to save on the massive medical expenses associated with severe illnesses such as cancer. This achieves the economic benefit of reducing expenditures for government health insurance, hospital operations, and patient medication benefits, thereby allowing more patient groups to receive treatment and improving their overall quality of life.
(The content above was translated by AI.)